Semaglutide sublingual dose: what the evidence actually says

What the trial evidence says about semaglutide's approved delivery routes

The clinical case for semaglutide in weight management rests on two distinct sets of evidence: the injection trials and, more recently, the oral tablet studies. The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity over 68 weeks using the 2.4 mg weekly subcutaneous injection. Participants lost an average of around 15% of their body weight. That figure has shaped prescribing expectations ever since.

For the tablet, Novo Nordisk ran the OASIS 4 phase 3 trial: 307 adults, 64 weeks, the highest oral maintenance dose of 25 mg daily. Average weight loss was around 13.6% against approximately 2.4% for placebo. Among participants who adhered fully to the trial protocol, the figure rose to roughly 17%. The MHRA approved the Wegovy tablet on 11 June 2026, making it the first oral GLP-1 medicine licensed in the UK for weight management. Neither of these trials used sublingual administration. The evidence base for sublingual semaglutide in humans is essentially absent from the peer-reviewed, regulatory-grade literature.

The reason a sublingual route is pharmacologically tricky for semaglutide is that the molecule is a large peptide. Small molecules can cross the mucous membrane under the tongue readily; large peptides generally cannot, at least not in meaningful quantities. The oral Wegovy tablet solves this differently: SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) creates a localised alkaline environment in the stomach that temporarily increases the permeability of the stomach lining. That mechanism only works when the stomach is empty and when the tablet is swallowed whole, not dissolved.

What the Wegovy tablet actually is, and how it differs from a sublingual preparation

Because the Wegovy tablet is taken by mouth, it is sometimes loosely described in non-clinical settings as an "oral" or even "dissolving" preparation. It is neither a sublingual tablet nor a buccal tablet. Swallowing it is the point. The NHS medicines page for semaglutide is clear that the tablet should be taken whole, first thing in the morning, with a small amount of plain water (no more than about 120 ml) on a completely empty stomach. You then wait at least 30 minutes before eating, drinking anything else (including coffee), or taking other oral medicines. Splitting, crushing or dissolving the tablet would disrupt the SNAC mechanism and reduce absorption.

Dose escalation for the tablet is gradual: starting at 1.5 mg daily, which is the lowest starting point on the Wegovy tablet schedule, moving through 4 mg and 9 mg steps to the 25 mg maintenance dose, with at least a month at each level. That ladder is fixed. If you've been searching for a sublingual dose equivalent, the honest answer is that no published conversion exists, because there is no licensed sublingual product to convert from. You can read more about how the weekly injection doses are structured on our semaglutide doses overview.

One practical difference worth noting: the tablet needs no refrigeration. The weekly injection pen is stored in a fridge at 2–8°C. For people who travel frequently or find cold-chain management inconvenient, the tablet removes that concern entirely. That said, convenience is a clinical decision shaped by individual circumstances, not a reason to choose one licensed option over another without guidance.

Why unlicensed compounded semaglutide preparations carry real risk

The search for a sublingual semaglutide dose is often driven by one of two things: the cost of licensed products, or a hope that an alternative format might cause fewer side effects. Both are understandable starting points, but neither is well-served by unlicensed compounded preparations. The MHRA has warned publicly about fake and unregulated GLP-1 products circulating online and through social media, some of which have contained entirely wrong active substances. A preparation described as sublingual semaglutide, sold without a prescription through an unverified channel, falls squarely into that risk category.

Licensed medicines go through extensive trials to establish that the dose stated on the label actually reaches the bloodstream in the quantity needed to be both safe and effective. An unlicensed compounded product has no such assurance. The MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk exists partly to capture adverse events from exactly these situations, and reporters can also flag suspect sellers through the same portal.

If the cost of licensed Wegovy is a genuine barrier, our Wegovy cost page explains what private treatment actually includes, what varies between providers, and why headline prices sometimes omit clinical and delivery costs. A prescription medicine sourced through an unverified route is rarely the saving it appears to be.

What a prescriber would consider if you're interested in oral semaglutide

For people who are eligible but prefer not to inject, the Wegovy tablet is now a real licensed option in the UK, and a prescriber can assess whether it fits your circumstances. Eligibility broadly follows the same framework as the injection: adults with a BMI of 30 or above, or 27–29.9 alongside at least one weight-related health condition, following a reduced-calorie diet and increased activity. Lower thresholds apply for some ethnic backgrounds under UK guidance. The prescriber looks at the whole picture, not just BMI, but medical history, current medicines, and how the morning-fasting requirement would work practically in your life.

The injectable Wegovy, meanwhile, retains the longest evidence base and the highest dose currently licensed in the UK, including the newer 7.2 mg option approved by the MHRA in April 2026 for adults with a BMI of 30 or above. The Wegovy overview page covers both formats and the differences between them. For a broader look at licensed weight-loss treatment options, our weight loss treatments page sets out the full picture. Semaglutide's dose schedule, whatever the format, is set by the prescriber, and our guide to semaglutide dosing explains how that process works in practice, including details on the 2 mg dose stage that applies to the injectable route. If you'd like our prescribers to assess your suitability, starting with a free consultation is the first step, with clinical review the same day by a GPhC-registered prescriber.